Table 3.

Treatment-emergent adverse events occurring in ≥5 % of subjects following oral administration of metformin alone, trospium chloride XR alone, or metformin and trospium chloride XR in combination [n (%)]

Adverse event	Metformin (n = 43)	Trospium chloride XR (n = 44)	Trospium chloride XR + metformin (n = 44)	Total (N = 44)
Headache	4 (9)	3 (7)	7 (16)	12 (27)
Diarrhoea	3 (7)	0 (0)	3 (7)	6 (14)
Abdominal distension	1 (2)	2 (5)	0 (0)	3 (7)
Abdominal pain, upper	3 (7)	0 (0)	0 (0)	3 (7)
Constipation	1 (2)	1 (2)	1 (2)	3 (7)
Dizziness	1 (2)	1 (2)	1 (2)	3 (7)
Dry throat	1 (2)	2 (5)	0 (0)	3 (7)
Nasal congestion	0 (0)	0 (0)	3 (7)	3 (7)
Abdominal pain	0 (0)	1 (2)	2 (5)	2 (5)
Dry lip	2 (5)	0 (0)	0 (0)	2 (5)
Metrorrhagia	2 (5)	0 (0)	0 (0)	2 (5)
Nausea	2 (5)	0 (0)	1 (2)	2 (5)
Oropharyngeal pain	0 (0)	1 (2)	1 (2)	2 (5)
Upper respiratory tract infection	0 (0)	0 (0)	2 (5)	2 (5)
Vomiting	1 (2)	0 (0)	1 (2)	2 (5)
White blood cells urine positive	1 (2)	1 (2)	0 (0)	2 (5)

XR extended release